Leukemia Clinical Trials in Chicago, Illinois

7 studies are recruiting for leukemia in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

2. Mosaic Trial for Stem Cell Transplant Recipients

   The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Northwestern University Feinberg School of Medicine, Chicago, Illinois

   Locations

   3 in total

   Run by

   Northwestern University

   See if you can join NCT06960993 on ClinicalTrials.gov

3. CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

   This is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, dexamethasone; (part …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07294677 on ClinicalTrials.gov

4. Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia

   This study is being done to determine if it is possible to incorporate spiritual care sessions as part of the care plan for patients hospitalized for leukemia treatment. In this study, participants will be randomly assigned to either no intervention (standard, real world inpatient spiritual care) o…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07405424 on ClinicalTrials.gov

5. Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

   The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   3 in total

   Run by

   University of Miami

   See if you can join NCT05745285 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Chicago, Illinois

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

7. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

   Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago, Illinois

   Locations

   13 in total

   Run by

   BlossomHill Therapeutics

   See if you can join NCT06501196 on ClinicalTrials.gov